Expert Review of Neurotherapeutics最新文献_第10页

What are the main challenges in the treatment of neonatal hypoxic ischemic encephalopathy? 新生儿缺氧缺血性脑病治疗的主要挑战是什么？

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-02-01 Epub Date: 2024-12-11 DOI: 10.1080/14737175.2024.2438649

Francesco Pisani, Carlotta Spagnoli

引用次数: 0

Evaluating the value and risks of psychedelics for psychiatric medicine: a clinical perspective. 评估致幻剂对精神医学的价值和风险：临床观点。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-02-01 Epub Date: 2024-12-23 DOI: 10.1080/14737175.2024.2445016

Donatella Marazziti, Francesco Weiss, Riccardo Gurrieri, Gerardo Russomanno, Matteo Gambini, Anna Magnesa, Andrea Coccoglioniti, Giulio Perugi

{"title":"Evaluating the value and risks of psychedelics for psychiatric medicine: a clinical perspective.","authors":"Donatella Marazziti, Francesco Weiss, Riccardo Gurrieri, Gerardo Russomanno, Matteo Gambini, Anna Magnesa, Andrea Coccoglioniti, Giulio Perugi","doi":"10.1080/14737175.2024.2445016","DOIUrl":"10.1080/14737175.2024.2445016","url":null,"abstract":"Introduction: After a long period of obscurantism, a possible role of psychedelics in clinical practice has progressively become a tangible perspective during the last two decades. However, the resounding enthusiasm linked to such 'psychedelic renaissance' runs the risk to unduly minimize the possible hazards associated with these compounds, while expanding their alleged benefits to improbable panacea-like proportions. In order to avoid mystifying or demonizing the properties of 5-HT2a agonists on emotional grounds, this subject requires a strictly unprejudiced and cautious approach to the evidence.Areas covered: In this article, the authors attempted to comprehensively analyze the available literature to provide a balanced overview of the possible benefits of psychedelics in healthcare, taking into account their potential risks.Expert opinion: To date, psychedelics have shown a therapeutic potential in a wide range of conditions, with a seemingly limited risk of inducing adverse reactions, including abuse and dependence, when administered in a controlled environment by specialized personnel. In any case, although several questions remain unanswered before drawing firm conclusions, further studies are needed to establish which conditions and subjects could benefit from psychedelics and which patients bear the greater risk of adversities.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"143-156"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An update on the treatment and management of cognitive dysfunction in patients with multiple sclerosis. 多发性硬化症患者认知功能障碍的治疗和管理进展。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-02-01 Epub Date: 2025-01-16 DOI: 10.1080/14737175.2025.2450788

Ermelinda De Meo, Emilio Portaccio, Raffaello Bonacchi, Jasmine Giovannoli, Claudia Niccolai, Maria Pia Amato

{"title":"An update on the treatment and management of cognitive dysfunction in patients with multiple sclerosis.","authors":"Ermelinda De Meo, Emilio Portaccio, Raffaello Bonacchi, Jasmine Giovannoli, Claudia Niccolai, Maria Pia Amato","doi":"10.1080/14737175.2025.2450788","DOIUrl":"10.1080/14737175.2025.2450788","url":null,"abstract":"Introduction: Cognitive impairment (CI) occurs in 34-70% of multiple sclerosis (MS) patients, significantly impacting quality of life. CI can occur independently of physical disability, even in those with 'benign MS.' Cognitive deficits are heterogeneous, but common areas affected include processing speed, memory, and executive functions.Areas covered: A comprehensive literature search was conducted across databases such as PubMed and Google Scholar, using keywords like 'MS,' 'cognition,' and 'cognitive rehabilitation.' We focused on clinical assessment tools, emerging cognitive phenotypes, and both pharmacological and non-pharmacological treatments, including disease-modifying therapies and cognitive rehabilitation techniques.Expert opinion: Current evidence underscores the need for a multifaceted approach to managing CI in MS, incorporating emerging pharmacological treatments, cognitive rehabilitation strategies, and exercise programs. Future research should prioritize defining optimal training intensities, integrating therapies for sustained cognitive enhancement, and exploring neuromodulation and neuroimaging biomarkers within randomized controlled trials aimed at improving cognitive functioning in MS.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"227-243"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Managing cognitive impairment in Parkinson's disease: an update of the literature. 帕金森病的认知障碍管理：文献更新。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-02-01 Epub Date: 2025-01-10 DOI: 10.1080/14737175.2025.2450668

Jennifer G Goldman, Priya Jagota, Elie Matar

{"title":"Managing cognitive impairment in Parkinson's disease: an update of the literature.","authors":"Jennifer G Goldman, Priya Jagota, Elie Matar","doi":"10.1080/14737175.2025.2450668","DOIUrl":"10.1080/14737175.2025.2450668","url":null,"abstract":"Introduction: Cognitive impairment in Parkinson's disease (PD) substantially affects patient outcomes, function, and quality of life. PD-related cognitive dysfunction is often heterogeneous in clinical presentation and rates of progression. As cognitive changes occur in many people with PD, it is essential to evaluate cognition, provide education, and implement management strategies for cognitive symptoms.Areas covered: This article describes the symptomatology, epidemiology, risk factors, and pathobiology of cognitive impairment in PD. Additionally, the article provides an overview of evidence-based management and other therapeutic and coping strategies for cognitive impairment and dementia in PD. Comment is offered on challenges and opportunities for trials and emerging therapeutics targeting cognitive symptoms or decline.Expert opinion: While our understanding of cognitive dysfunction in PD has grown, effective and safe therapeutics are still needed to not only treat cognitive impairment and dementia symptomatically but also slow down or prevent cognitive decline. Further research is needed to elucidate the pathobiology of PD cognitive impairment, develop validated biomarkers reflecting cognitive change, and ultimately, integrate clinical and biological frameworks. Consensus regarding cognitive evaluations, definitions, and criteria of cognitive impairment, evaluating functional abilities in the context of cognitive impairment, and determining optimal outcome measures for clinical trials remain unmet needs.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"189-209"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142947067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Expert guidance on the differential diagnosis of neuroleptic malignant syndrome. 神经安定剂恶性综合征鉴别诊断专家指导。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-02-01 Epub Date: 2024-10-18 DOI: 10.1080/14737175.2024.2417414

Laura Orsolini, Umberto Volpe

引用次数: 0

Therapeutic barriers for headache management: issues facing the global north and global south in 2024. 头痛管理的治疗障碍：2024年全球北方和全球南方面临的问题。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-01-10 DOI: 10.1080/14737175.2025.2450647

William David Wells-Gatnik, Paolo Martelletti

引用次数: 0

Neuromodulation as a therapeutic approach for post-traumatic stress disorder: the evidence to date. 神经调节作为创伤后应激障碍的治疗方法：迄今为止的证据。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-01-01 Epub Date: 2024-12-24 DOI: 10.1080/14737175.2024.2442658

Felicia Manocchio, Jordan Enepekides, Sean Nestor, Peter Giacobbe, Jennifer S Rabin, Matthew J Burke, Krista L Lanctôt, Maged Goubran, Ying Meng, Nir Lipsman, Clement Hamani, Benjamin Davidson

{"title":"Neuromodulation as a therapeutic approach for post-traumatic stress disorder: the evidence to date.","authors":"Felicia Manocchio, Jordan Enepekides, Sean Nestor, Peter Giacobbe, Jennifer S Rabin, Matthew J Burke, Krista L Lanctôt, Maged Goubran, Ying Meng, Nir Lipsman, Clement Hamani, Benjamin Davidson","doi":"10.1080/14737175.2024.2442658","DOIUrl":"10.1080/14737175.2024.2442658","url":null,"abstract":"Introduction: Post-traumatic stress disorder (PTSD) can have debilitating effects on quality of life, and conventional treatments show mixed results. Neuromodulation is emerging as a promising approach for treating PTSD. This review examines current neuromodulatory treatments for PTSD, and highlights methodologies, clinical outcomes, and gaps in the literature to help guide future research.Areas covered: A PubMed search identified 252 studies on PTSD and neuromodulation, of which 61 were selected for full review. These included 37 studies on repetitive transcranial magnetic stimulation (rTMS), 10 on transcranial direct current stimulation (tDCS),4 on deep brain stimulation (DBS) and 2 on focused ultrasound (FUS).Expert opinion: The present review supports the potential of neuromodulation to reduce PTSD symptoms. rTMS and tDCS targeting the dlPFC appear effective through modulating neural circuits involved in fear processing and conditioning, however, literature varies regarding efficacy of stimulation frequencies and hemispheric targets. DBS targeting the amygdala or subcallosal cingulate white matter tracts improves treatment of refractory PTSD with sustained benefits, while FUS may improve symptoms through targeted modulation of brain structures such as the amygdala, though this technique is in the early stages of exploration. Future research should refine established neuromodulatory approaches and address gaps in emerging modalities to enhance treatment efficacy.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"101-120"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142863894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The value of hypothermia as a neuroprotective and antiepileptic strategy in patients with status epilepticus: an update of the literature. 低体温作为神经保护和抗癫痫策略对癫痫状态患者的价值：文献更新。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-01-01 Epub Date: 2024-11-24 DOI: 10.1080/14737175.2024.2432869

Stéphane Legriel, Candice Fontaine, Gwenaelle Jacq

引用次数: 0

Essential tremor - drug treatments present and future. 原发性震颤-药物治疗的现在和未来。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-01-01 Epub Date: 2024-12-16 DOI: 10.1080/14737175.2024.2439514

Hortensia Alonso-Navarro, Elena García-Martín, José A G Agúndez, Félix Javier Jiménez-Jiménez

{"title":"Essential tremor - drug treatments present and future.","authors":"Hortensia Alonso-Navarro, Elena García-Martín, José A G Agúndez, Félix Javier Jiménez-Jiménez","doi":"10.1080/14737175.2024.2439514","DOIUrl":"10.1080/14737175.2024.2439514","url":null,"abstract":"Introduction: The main treatment options for essential tremor (ET), which is probably one of the most common movement disorders, have been propranolol and primidone, for many years. This review aims to synthesize therapeutic attempts with other drugs.Areas covered: We have reviewed the current state of the pharmacological treatment of ET, both in patients and in experimental models of this disease, with special emphasis on the data published in the last 5 years. Based on the results in experimental models of ET, proposals have been made for future alternative therapeutic options.Expert opinion: The use of drugs other than propranolol and primidone has not shown a greater degree of efficacy than these in the treatment of ET, although according to certain evidence-based guidelines topiramate and phenobarbital could be alternative drugs. The results on the effectiveness of other drugs have been variable. For patients with refractory ET, especially those with head tremor, local injections with botulinum toxin A may be useful. According to the results of various experimental models, T calcium channel blockers, modulators of GABAA receptors (GABAARs), GABAB receptors (GABABRs), and glutamatergic neurotransmission, and drugs that decrease the expression of LINGO-1 could be interesting options for the future, among others.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"43-56"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Promising therapeutic strategies for Lennox-Gastaut syndrome: what's new? lenox -胃综合征有前景的治疗策略：有什么新进展？

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-01-01 Epub Date: 2024-12-21 DOI: 10.1080/14737175.2024.2439512

Frank M C Besag, Michael J Vasey, Richard J Brown

{"title":"Promising therapeutic strategies for Lennox-Gastaut syndrome: what's new?","authors":"Frank M C Besag, Michael J Vasey, Richard J Brown","doi":"10.1080/14737175.2024.2439512","DOIUrl":"10.1080/14737175.2024.2439512","url":null,"abstract":"Introduction: The seizures in Lennox-Gastaut syndrome are typically resistant to treatment. Seven antiseizure medications (ASMs) in the US (six in the UK/EU) are licensed for the treatment of seizures in LGS: lamotrigine, topiramate, rufinamide, clobazam, felbamate (not licensed in the UK/EU), cannabidiol and fenfluramine. Other options include neurostimulation, corpus callosotomy and dietary therapies, principally the ketogenic diet and its variants. New treatments and therapeutic strategies are needed to improve management of both seizures and cognitive/behavioral comorbidities in LGS.Areas covered: Embase and Medline were searched for articles published between 1 January 2014 and 21 August 2024 reporting efficacy data for pharmacological, neurostimulation, surgical and dietary interventions in individuals with LGS focusing on recent advances. Ongoing and prospective studies were identified from the National Library of Medicine register of clinical trials.Expert opinion: LGS remains a difficult-to-treat epilepsy. Although no major breakthroughs have been reported, several established and novel ASMs, some surgical strategies and other treatment approaches are of benefit or are showing promise. Progress remains incremental but any improvements in the management of this resistant epilepsy syndrome are worthwhile.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"15-27"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0